Nattokinase and Long COVID Microclots: What the Fibrinaloid Clot Research Actually Shows

Long COVID and ME/CFS research has increasingly focused on “fibrinaloid microclots,” an abnormal, amyloid-like form of fibrin that resists normal clot-dissolving processes and is thought to obstruct capillary blood flow, potentially explaining some of the fatigue, brain fog, and exercise intolerance reported by patients. Because nattokinase is a well-characterized fibrin-degrading enzyme, it has drawn attention as a possible tool against these microclots specifically, separate from its cardiovascular research, where trial results are mixed ^[3][4]. This article covers what the actual laboratory evidence shows, and where it stops.

What Fibrinaloid Microclots Are

Researchers Resia Pretorius and Douglas Kell have described a mechanism in which fibrinogen polymerizes into an abnormal, amyloid-like form during or after certain infections, creating microclots that are structurally different from normal fibrin and resistant to the body’s usual fibrinolytic machinery. These fibrinaloid microclots have been identified at elevated levels in Long COVID and ME/CFS patients, and the working hypothesis is that they obstruct the smallest capillaries, potentially starving tissue of oxygen and contributing to fatigue and cognitive symptoms.

The 2024 Degradation Study

A 2024 study developed an automated microscopic method to quantify fibrinaloid microclot formation and kinetics, then tested recombinant nattokinase’s ability to break them down. The enzyme degraded the microclots effectively in vitro, with, according to the preprint authors, a half-life to noticeable clot reduction of approximately two hours, and both tested doses (14 ng/µL and 28 ng/µL) were effective without over-digesting the sample, suggesting a workable dosing window in the lab model^[1]. The researchers themselves characterized the broader therapeutic case for nattokinase in Long COVID as still resting largely on anecdotal patient reports layered on top of this laboratory data, explicitly calling for controlled clinical trials.

Not every lab result points the same way. A separate 2026 lab model of amyloid microclots made from plasma found that nattokinase on its own did not significantly shrink the clots, and adding ultrasound added little. A 2026 long COVID treatment review says there are no human studies suggesting nattokinase helps long COVID and none underway or planned, and it describes a proposed nattokinase, bromelain and curcumin protocol as untested ^[5][6][7].

Editor’s Pick

Nattokinase Supplement 4,000 FU Servings, 120 Capsules

Double Wood’s label is unusually specific about what you are actually getting: each capsule carries 100 mg standardised to 2,000 FU, so the two-capsule serving is 4,000 FU. Worth knowing what that 2,000 FU figure does and does not mean: it is the dose used in the largest and longest randomised trial of nattokinase (265 adults, median three years), and that trial found no effect on carotid artery thickening, arterial stiffness, blood pressure or any laboratory measure. Treat it as the dose that has been properly tested, not a dose shown to work. The 120-count bottle is about two months at that serving. Third-party tested, vegetarian, non-GMO and gluten-free. Because the enzyme is fermented from Japanese natto, the label carries a trace-soy warning that matters if you react to soy.

Capsules2,000 FU/cap120 count

Check Price on Amazon › As an Amazon Associate we earn from qualifying purchases.

The Spike Protein Angle

A separate line of research examined whether nattokinase could degrade the SARS-CoV-2 spike protein itself. When cell lysates expressing the spike protein were incubated with nattokinase, the protein was degraded in a dose- and time-dependent manner, and immunofluorescence imaging confirmed degradation of spike protein present on the cell surface^[2]. This matters to the Long COVID discussion because persistent spike protein, whether from residual viral reservoirs or circulating fragments, is hypothesized by some researchers to be a driver of ongoing endothelial inflammation. This study, like the microclot work, was conducted in cell culture, not in Long COVID patients.

Premium Pick

Nattokinase 50mg/1000FU 90 Capsules – 2 Pack

A practitioner-channel brand rather than a mass-market one, and it doses differently on purpose: 50 mg (1,000 FU) per capsule, taken one capsule three times daily before meals, so enzyme activity is spread across the day instead of arriving in a single 4,000 FU hit. The listing is a two-pack, 180 capsules in total. Pick it if you specifically want divided dosing or your practitioner asked for this brand. If you just want the standard once-daily serving, the higher-potency options are simpler.

Capsules1,000 FU/cap180 count

Check Price on Amazon › As an Amazon Associate we earn from qualifying purchases.

What This Doesn’t Establish

Two in vitro findings, however mechanistically interesting, are not the same as a clinical trial showing that oral nattokinase supplementation reduces microclot burden or improves symptoms in Long COVID or ME/CFS patients. Oral nattokinase must survive digestion and reach the bloodstream in active form to have any systemic fibrinolytic effect, a bioavailability question that hasn’t been specifically tested for microclot degradation in living patients. Anyone with Long COVID or ME/CFS considering nattokinase for this reason should discuss it with a physician familiar with their case, particularly given the drug interaction and bleeding-risk profile nattokinase already carries for cardiovascular use, and should not treat the current evidence as equivalent to a proven therapy.

Frequently Asked Questions

Does nattokinase cure Long COVID microclots?

No clinical trial has established that. Laboratory research shows nattokinase degrades fibrinaloid microclots in vitro, but this hasn’t been tested as a treatment in Long COVID or ME/CFS patients through a controlled clinical trial.

What are fibrinaloid microclots?

They are an abnormal, amyloid-form fibrin structure identified at elevated levels in Long COVID and ME/CFS patients, believed to resist normal clot-dissolving processes and potentially obstruct capillary blood flow.

Is it safe to take nattokinase for Long COVID symptoms?

Anyone considering this should talk to a physician first, particularly because nattokinase carries known bleeding-risk and drug-interaction considerations for cardiovascular use, and its effect on microclots in actual patients hasn’t been established in a clinical trial.

References

1. Kruger A et al. Automated microscopic measurement of fibrinaloid microclots and their degradation by nattokinase, the main natto protease. bioRxiv preprint (2024). bioRxiv
2. Tanikawa T et al. Degradative Effect of Nattokinase on Spike Protein of SARS-CoV-2. Molecules (2022). PMID 36080170
3. Hodis HN et al. Nattokinase atherothrombotic prevention study: A randomized controlled trial. Clinical hemorheology and microcirculation (2021). PMID 33843667
4. Li X et al. Nattokinase Supplementation and Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Reviews in cardiovascular medicine (2023). PMID 39076715
5. Rasouli R et al. Investigation of the synergistic effect of enzymatic and Ultrasound-Induced amyloid microclot degradation. Journal of thrombosis and thrombolysis (2026). PMID 41405757
6. Baptista SN et al. Candidate treatments for long COVID: a narrative review of expert and patient-driven priorities. Frontiers in medicine (2026). PMID 41836927
7. Hulscher N et al. Clinical Approach to Post-acute Sequelae After COVID-19 Infection and Vaccination. Cureus (2023). PMID 38024037

These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.